Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony‐stimulating factor preceding allogeneic bone marrow transplantation
Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony‐stimulating factor preceding allogeneic bone marrow transplantation
复制标题
异基因骨髓移植前采用重组人粒细胞集落刺激因子治疗晚期骨髓增生异常综合征
DOI：
--
复制
发表时间：
1999
影响因子：
6.5
通讯作者：
S. Asano
中科院分区：
文献类型：
--
作者：
S. Okamoto;Satoshi Takahashi;M. Wakui;A. Ishida;R. Tanosaki;Yasuo Ikeda;S. Asano
我们使用阿糖胞苷和全身照射治疗了13例形态学晚期骨髓增生异常综合征患者，随后进行了HLA相合同胞供者的异基因骨髓移植。将粒细胞集落刺激因子（G-CSF）添加到准备方案中，以选择性地增加白血病细胞的化学敏感性并改善移植结果。未发生方案相关死亡，除一过性轻度骨痛外，未观察到与添加G-CSF相关的副作用。中位随访时间为39个月，预计5年无病生存率和5年总生存率分别为67.7%和75.5%，仅1例病例显示细胞遗传学复发。包括G-CSF的制备方案是可行的，初步结果似乎令人鼓舞。然而，显然需要进行更大规模的试验来评估其疗效。
We treated 13 patients with morphologically advanced myelodysplastic syndrome using cytosine arabinoside and total body irradiation, followed by allogeneic marrow transplantation from HLA‐identical sibling donors. Granulocyte colony‐stimulating factor (G‐CSF) was added to the preparative regimen to selectively increase chemosensitivity of leukaemic cells and to improve transplant outcome. No regimen‐related deaths occurred, and no side‐effects related to the addition of G‐CSF were observed except for transient mild bone pain. At a median follow‐up time of 39 months the projected 5‐year disease‐free survival and 5‐year overall survival were 67.7% and 75.5%, respectively, with only one case showing cytogenetic relapse. The preparative regimen including G‐CSF is feasible, and preliminary results seem to be encouraging. However, a larger trial is clearly warranted to evaluate its efficacy.
同种异体骨髓移植治疗骨髓增生异常综合征93例。
影响因子：
20.3
作者：
Anderson,JE;Appelbaum,FR;Fisher,LD;Schoch,G;Shulman,H;Anasetti,C;Bensinger,WI;Bryant,E;Buckner,CD;Doney,K
通讯作者：
Doney,K